These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of hyporesponsiveness to augmentation of natural killer cell activity after multiple doses of maleic anhydride divinyl ether: association with decreased numbers of large granular lymphocytes. Saito T; Welker RD; Fukui H; Herberman RB; Chirigos MA Cell Immunol; 1985 Feb; 90(2):577-89. PubMed ID: 3871375 [TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT. Black PL; McKinnon KM; Wooden SL; Ussery MA Int J Immunopharmacol; 1996 Nov; 18(11):633-50. PubMed ID: 9089007 [TBL] [Abstract][Full Text] [Related]
6. Development of hyporesponsiveness of natural killer cells to augmentation of activity after multiple treatments with biological response modifiers. Saito T; Ruffman R; Welker RD; Herberman RB; Chirigos MA Cancer Immunol Immunother; 1985; 19(2):130-5. PubMed ID: 3845849 [TBL] [Abstract][Full Text] [Related]
7. Comparison of in vitro and in vivo modulation of myelopoiesis by biological response modifiers. Schlick E; Hartung K; Chirigos MA Cancer Immunol Immunother; 1984; 18(3):226-32. PubMed ID: 6334554 [TBL] [Abstract][Full Text] [Related]
8. Role of NK cells in immunomodulator-mediated resistance to herpesvirus infection. Kunder SC; Wu L; Morahan PS Antiviral Res; 1993 Jun; 21(2):103-18. PubMed ID: 8393316 [TBL] [Abstract][Full Text] [Related]
9. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo. Bukowski JF; Welsh RM J Immunol; 1985 Nov; 135(5):3537-41. PubMed ID: 2413125 [TBL] [Abstract][Full Text] [Related]
11. The effect of biological response modifiers on chronic and latent murine cytomegalovirus infections. Okada M; Minamishima Y Microbiol Immunol; 1987; 31(5):435-47. PubMed ID: 2443815 [TBL] [Abstract][Full Text] [Related]
12. In vivo induction of terminal differentiation of malignant myelopoietic progenitor cells by CSF-inducing biological response modifiers. Schlick E; Ruscetti FW Blood; 1986 Apr; 67(4):980-7. PubMed ID: 3485461 [TBL] [Abstract][Full Text] [Related]
13. Host defense mechanisms against murine cytomegalovirus infection induced by poly I:C in severe combined immune deficient (SCID) mice. Ikeda S; Neyts J; De Clercq E Proc Soc Exp Biol Med; 1994 Nov; 207(2):191-6. PubMed ID: 7524103 [TBL] [Abstract][Full Text] [Related]
14. Antibody-independent protection in mice against type Ia group B streptococcus lethal infection. Scaringi L; Tissi L; Cornacchione P; Rosati E; Campanelli C; von Hunolstein C; Orefici G; Rossi R; Marconi P FEMS Immunol Med Microbiol; 1994 Aug; 9(2):151-62. PubMed ID: 7804166 [TBL] [Abstract][Full Text] [Related]
15. Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection. Morahan PS; Pinto A; Stewart D; Murasko DM; Brinton MA Antiviral Res; 1991; 15(3):241-54. PubMed ID: 1653557 [TBL] [Abstract][Full Text] [Related]
16. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. Salazar-Mather TP; Ishikawa R; Biron CA J Immunol; 1996 Oct; 157(7):3054-64. PubMed ID: 8816415 [TBL] [Abstract][Full Text] [Related]
17. Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2. Zhang SR; Salup RR; Urias PE; Twilley TA; Talmadge JE; Herberman RB; Wiltrout RH Cancer Immunol Immunother; 1986; 21(1):19-25. PubMed ID: 3484675 [TBL] [Abstract][Full Text] [Related]
18. Immune response by biological response modifiers. Chirigos MA; Schlick E; Budzynski W Cancer Detect Prev Suppl; 1987; 1():385-97. PubMed ID: 3500779 [TBL] [Abstract][Full Text] [Related]
19. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. Orange JS; Wang B; Terhorst C; Biron CA J Exp Med; 1995 Oct; 182(4):1045-56. PubMed ID: 7561678 [TBL] [Abstract][Full Text] [Related]
20. Biological characterization of MVE-2 and poly ICLC. Schlick E; Welker R; Piccoli M; Ruffmann R; Chirigos M Prog Clin Biol Res; 1984; 161():511-24. PubMed ID: 6483902 [No Abstract] [Full Text] [Related] [Next] [New Search]